NIH PAR · NIA · UG3, UH3

PAR-25-226: Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards

Open for applicationsNext due date: Oct 19, 2026Expires Nov 20, 2026

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award…

Full NOFO in the NIH Guide Apply on Grants.gov

NOFO number
PAR-25-226
Type
PAR
Activity code
UG3UH3
Primary institute
NIA · National Institute on Aging
Clinical trials
Required
Posted
Nov 22, 2024
Opens
Jan 21, 2025
Expires
Nov 20, 2026

PAR-25-226 due dates

1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.

Application due dates and review cycles for PAR-25-226
Application Due Date(s)Renewal / Resubmission / Revision (as allowed)AIDS - New/Renewal/Resubmission/Revision, as allowedScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
February 21, 2025March 21, 2025Not ApplicableJune 2025October 2025December 2025
June 23, 2025July 23, 2025Not ApplicableOctober 2025January 2026April 2026
October 20, 2025November 20, 2025Not ApplicableFebruary 2026May 2026July 2026
February 20, 2026March 20, 2026Not ApplicableJune 2026October 2026December 2026
June 22, 2026July 22, 2026Not ApplicableOctober 2026January 2027April 2027
October 19, 2026November 19, 2026Not ApplicableFebruary 2027May 2027July 2027

Projects funded under PAR-25-226

NIH RePORTER lists 6 projects funded under PAR-25-226 in FY2022–FY2026, with $18.3M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.

Projects funded

6

Distinct projects, FY2022–FY2026

New awards

6

Type 1 (new project) award records

NIH funding

$18.3M

Award dollars under PAR-25-226, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under PAR-25-226
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202300$0
FY202400$0
FY202500$0
FY202666$18.3M

Institutions with the most funding

  1. University of Arizona$6.3M · 1 project
  2. Johns Hopkins University$4.0M · 1 project
  3. Weill Medical Coll of Cornell Univ$3.3M · 1 project
  4. Artery Therapeutics, Inc.$2.6M · 1 project
  5. Brigham and Women's Hospital$1.5M · 1 project
  6. Case Western Reserve University$496K · 1 project

Funding institutes

  • NIA$18.3M · 6

Activity codes funded

  • UG36 records

Most recent new awards

FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.

Participating institutes

2 NIH institutes and offices take applications under PAR-25-226. Contact the program officer at the institute that fits your research before applying.

  • NIA · National Institute on Aging
  • none

Related notices

  1. Mar 31, 2025 · NOT-OD-24-084

    This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…

  2. Aug 31, 2022 · NOT-OD-22-198

    Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.

  3. Aug 5, 2022 · NOT-OD-22-189

    Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.

Award terms

Application types allowed
NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Award budget
Application budgets are not limited but need to reflect the actual needs of the proposed project.
Project period
The scope of the proposed project should determine the project period. The proposed project period for the UG3 phase must not exceed 2 years. The total duration of the UG3/UH3 phases combined must not exceed 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Funds available and number of awards
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. 

Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.

Related NOFOs

  • Reissue of PAR-23-274.

Other open NOFOs for UG3, UH3

Browse all open NIH NOFOs

About this page

GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.

Find who wins under this NOFO

NIH grant searchLook up awards by topic, PI, or institution.Find funded PIsInvestigators with recent NIH awards in your research area.Institute fit by topicWhich NIH institutes and institutions lead a research area.Funding trendsYear-by-year NIH award totals for any keyword.